|
14 Aug 2020 |
Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody
|
|
13 Aug 2020 |
Novo Nordisk resumes the phase 3 clinical trials investigating concizumab (anti-TFPI mAB) in haemophilia A and B with or without inhibitors
|
|
12 Aug 2020 |
Celleron Therapeutics enters into a license agreement with Roche to improve the lives of patients living with tenosynovial giant cell tumour
|
|
12 Aug 2020 |
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
|
|
12 Aug 2020 |
KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors
|
|
11 Aug 2020 |
SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-185 for the Treatment and Prevention of COVID-19
|
|
11 Aug 2020 |
Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875
|
|
11 Aug 2020 |
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
|
|
11 Aug 2020 |
FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy
|
|
11 Aug 2020 |
CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
|
|
11 Aug 2020 |
CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers
|
|
11 Aug 2020 |
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results
|
|
10 Aug 2020 |
AnaptysBio Reports Top-Line Data From Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
|
|
10 Aug 2020 |
Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer
|
|
10 Aug 2020 |
Genentech Provides Update on Phase III Studies of Etrolizumab in People With Moderately to Severely Active Ulcerative Colitis
|
|
08 Aug 2020 |
Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
|
|
07 Aug 2020 |
FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
|
|
07 Aug 2020 |
CStone Announces CS1001 (Anti-PD-L1 mAb) Phase III Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Plans to Submit a New Drug Application
|
|
07 Aug 2020 |
Genentech Provides Update On Phase III Study Of Tecentriq In Combination With Paclitaxel For People With Metastatic Triple-Negative Breast Cancer
|
|
07 Aug 2020 |
Novartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
|
|
06 Aug 2020 |
Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer
|
|
06 Aug 2020 |
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
|
|
04 Aug 2020 |
Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations
|
|
03 Aug 2020 |
Innovent Announces First Patient Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody in China
|
|
03 Aug 2020 |
AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration
|
